UK pharma major GlaxoSmithKline’s (LSE: GSK) Tafinlar (dabrafenib) is now available for metastatic melanoma patients in England after it was approved by NHS England to be routinely funded by the Cancer Drugs Fund (CDF) yesterday.
The European Medicines Agency granted marketing authorization for Tafinlar in monotherapy for the treatment of adult patients with unresectable melanoma or metastatic melanoma in August last year. Last month Tafinlar was approved by the US Food and Drug Administration in combination with Mekinist (trametinib). The melanoma drug market is forecast by Decision Resources to grow to $1.5 billion in 2020 in the world’s leading markets.
Tafinlar is indicated for melanoma with a mutated BRAF protein – specifically the BRAF V600 genetic mutation. If found early and confined to the skin, melanoma can usually be removed with surgery, but sometimes melanoma can spread to other parts of the body. If melanoma metastasizes, it becomes more difficult to treat and can be fatal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze